122 related articles for article (PubMed ID: 32710188)
1. Microtubule-organizing center-mediated structural atypia in low- and high-grade urothelial carcinoma.
Murata SI; Kuroda M; Kawamura N; Warigaya K; Musangile FY; Matsuzaki I; Kojima F
Virchows Arch; 2021 Feb; 478(2):327-334. PubMed ID: 32710188
[TBL] [Abstract][Full Text] [Related]
2. Microtubule-organizing center-mediated nuclear polarity in various normal and neoplastic human tissues.
Murata S; Warigaya K; Matsuzaki I; Itonaga M; Shimizu Y; Shuto M
Virchows Arch; 2015 Jun; 466(6):625-35. PubMed ID: 25742907
[TBL] [Abstract][Full Text] [Related]
3. Keratin 17 is a sensitive and specific biomarker of urothelial neoplasia.
Babu S; Mockler DC; Roa-Peña L; Szygalowicz A; Kim NW; Jahanfard S; Gholami SS; Moffitt R; Fitzgerald JP; Escobar-Hoyos LF; Shroyer KR
Mod Pathol; 2019 May; 32(5):717-724. PubMed ID: 30443013
[TBL] [Abstract][Full Text] [Related]
4. Immunohistochemical analysis of chromatin remodeler DAXX in high grade urothelial carcinoma.
Zizzi A; Montironi MA; Mazzucchelli R; Scarpelli M; Lopez-Beltran A; Cheng L; Paone N; Castellini P; Montironi R
Diagn Pathol; 2013 Jul; 8():111. PubMed ID: 23819605
[TBL] [Abstract][Full Text] [Related]
5. Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer.
Hensley PJ; Zetter D; Horbinski CM; Strup SE; Kyprianou N
Hum Pathol; 2016 Nov; 57():68-77. PubMed ID: 27402302
[TBL] [Abstract][Full Text] [Related]
6. Nuclear size measurement for distinguishing urothelial carcinomas from reactive urothelium on tissue sections.
Poropatich K; Yang JC; Goyal R; Parini V; Yang XJ
Diagn Pathol; 2016 Jun; 11(1):57. PubMed ID: 27357719
[TBL] [Abstract][Full Text] [Related]
7. Large nested variant of urothelial carcinoma: 23 cases mimicking von Brunn nests and inverted growth pattern of noninvasive papillary urothelial carcinoma.
Cox R; Epstein JI
Am J Surg Pathol; 2011 Sep; 35(9):1337-42. PubMed ID: 21836490
[TBL] [Abstract][Full Text] [Related]
8. Noninvasive low-grade papillary urothelial carcinoma with degenerative nuclear atypia: a grading pitfall.
Matoso A; Parimi V; Epstein JI
Hum Pathol; 2021 Jul; 113():1-8. PubMed ID: 33887303
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of the reduction of UT-B expression in urothelial carcinoma of the bladder.
Li C; Xue H; Lei Y; Zhu J; Yang B; Gai X
Pathol Res Pract; 2014 Dec; 210(12):799-803. PubMed ID: 25445116
[TBL] [Abstract][Full Text] [Related]
10. p-120 Catenin is a Useful Diagnostic Biomarker for Distinguishing Plasmacytoid and Sarcomatoid Variants From Conventional Urothelial Carcinoma.
Acosta AM; Barletta J; Sonpavde G; Schnitt S; Hirsch MS
Arch Pathol Lab Med; 2021 Aug; 145(8):1000-1008. PubMed ID: 33237989
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical Differentiation of Plasmacytoid Urothelial Carcinoma From Secondary Carcinoma Involvement of the Bladder.
Borhan WM; Cimino-Mathews AM; Montgomery EA; Epstein JI
Am J Surg Pathol; 2017 Nov; 41(11):1570-1575. PubMed ID: 28786878
[TBL] [Abstract][Full Text] [Related]
12. Utility of uroplakin II expression as a marker of urothelial carcinoma.
Tian W; Guner G; Miyamoto H; Cimino-Mathews A; Gonzalez-Roibon N; Argani P; Li X; Sharma R; Subhawong AP; Rezaei K; Bivalacqua TJ; Epstein JI; Bishop JA; Netto GJ
Hum Pathol; 2015 Jan; 46(1):58-64. PubMed ID: 25449628
[TBL] [Abstract][Full Text] [Related]
13. Association of current molecular subtypes in urothelial carcinoma with patterns of muscularis propria invasion.
Haghayeghi K; Lu S; Matoso A; Schiff SF; Mueller-Leonhard C; Amin A
Virchows Arch; 2021 Sep; 479(3):515-521. PubMed ID: 34218288
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap.
Nguyen JK; Przybycin CG; McKenney JK; Magi-Galluzzi C
Hum Pathol; 2020 Apr; 98():81-88. PubMed ID: 32142835
[TBL] [Abstract][Full Text] [Related]
15. Protein expression and amplification of AIB1 in human urothelial carcinoma of the bladder and overexpression of AIB1 is a new independent prognostic marker of patient survival.
Luo JH; Xie D; Liu MZ; Chen W; Liu YD; Wu GQ; Kung HF; Zeng YX; Guan XY
Int J Cancer; 2008 Jun; 122(11):2554-61. PubMed ID: 18246597
[TBL] [Abstract][Full Text] [Related]
16. ARID1A alteration in aggressive urothelial carcinoma and variants of urothelial carcinoma.
Li J; Lu S; Lombardo K; Monahan R; Amin A
Hum Pathol; 2016 Sep; 55():17-23. PubMed ID: 27137986
[TBL] [Abstract][Full Text] [Related]
17. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
18. Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: an analysis of cytokeratin 20, p53, and CD44 antigens.
McKenney JK; Desai S; Cohen C; Amin MB
Am J Surg Pathol; 2001 Aug; 25(8):1074-8. PubMed ID: 11474293
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target.
Go H; Kim PJ; Jeon YK; Cho YM; Kim K; Park BH; Ku JY
Eur J Cancer; 2015 Sep; 51(14):1937-45. PubMed ID: 26238015
[TBL] [Abstract][Full Text] [Related]
20. Survivin nuclear labeling index: a superior biomarker in superficial urothelial carcinoma of human urinary bladder.
Yin W; Chen N; Zhang Y; Zeng H; Chen X; He Y; Wang X; Zhou Q
Mod Pathol; 2006 Nov; 19(11):1487-97. PubMed ID: 16892011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
